Complete reponse in US for Genasense in CLL
This article was originally published in Scrip
Executive Summary
Genta's amendment to its NDA for its novel antisense anticancer drug Genasense (oblimersen sodium) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) has been accepted by the US FDAas a "complete response".